[Inhaled chemotherapy - Part 1: General concept and current technological challenges].

Area of Science:

• Oncology
• Pulmonary Medicine
• Nanomedicine

Background:

• Chemotherapy is a standard lung tumor treatment but has severe adverse effects.
• Pulmonary drug delivery and nanomedicine offer strategies to improve lung cancer treatment.
• Current inhalation techniques limit the effectiveness and safety of aerosolized chemotherapy for lung tumors.

Purpose of the Study:

• To review recent preclinical developments in pulmonary drug delivery for lung tumors.
• To address limitations of current aerosolized chemotherapy for lung cancer.
• To explore advanced formulations and inhalation devices for improved lung tumor treatment.

Main Methods:

• Review of recent preclinical research on aerosolized chemotherapy.
• Analysis of novel inhalation devices, specifically dry powder inhalers.
• Examination of advanced drug formulations including nanomedicine and controlled-release systems.

Main Results:

• Preclinical developments show promise in overcoming limitations of aerosolized chemotherapy.
• Dry powder inhalers offer a potential improvement over current inhalation techniques.
• Advanced formulations like controlled-release and nanomedicine-based approaches enhance drug delivery.

Conclusions:

• Innovations in inhalation devices and drug formulations are crucial for effective and safe pulmonary chemotherapy.
• Nanomedicine-based and controlled-release formulations represent promising strategies for lung tumor treatment.
• Further preclinical development is needed to optimize these advanced pulmonary drug delivery systems.